Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2003
Business Overview: ImmuCell develops, acquires, manufactures, and sells products to improve the health and productivity of cows for the dairy and beef industry. The company operates in a single reportable segment.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2003 | Six Months Ended June 30, 2002 |
|---|---|---|
| Total Revenues | $1,743,977 | $3,453,815 |
| Net Income | $576,992 | $146,431 |
| Net Income Per Share (Diluted) | $0.21 | $0.05 |
| Operating Cash Flow | $1,298,075 | $372,924 |
| Cash and Cash Equivalents (Ending) | $3,980,947 | $1,299,280 |
| Total Assets | $8,116,872 | $7,513,393 |
| Long-Term Debt | $0 | $0 |
| Working Capital | $5,398,593 | $4,227,642 |
Note: Gross margin for product sales was 56% for the six months ended June 30, 2003, compared to 46% in the prior year period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 50% ($1.71 million) compared to the prior year. This is primarily due to the early termination of a product license (Kamar Heatmount Detector) effective October 1, 2002, which eliminated significant sales volume from the 2002 comparison period.
- Profitability Surge: Despite lower revenues, Net Income increased by 294% ($430,561). This was driven by a one-time gain of $1,100,000 recorded in the first quarter of 2003 from the sale of the company's 50% interest in the AgriCell Company, LLC joint venture.
- Expense Reduction: Sales and marketing expenses dropped 66% ($512,000) due to the license termination. Conversely, Research and Development (R&D) expenses increased 45% ($187,000) to $604,000, reflecting heavy investment in the development of "Mast Out," a new product for treating mastitis in dairy cows.
- Liquidity Improvement: Cash and cash equivalents increased by $1.62 million, bolstered by strong operating cash flows and the proceeds from the joint venture sale.
Guidance, Outlook, and Risks
- Product Development: The primary focus is the development of "Mast Out." Pre-pivotal efficacy and safety studies were initiated in July 2003. The company anticipates initiating pivotal FDA trials in the first quarter of 2004, with completion expected in 2004.
- Financial Outlook: Management believes the $1.1 million one-time gain ensures annual profitability for 2003 despite increased R&D costs. The company expects to maintain profitable operations on an annual basis as animal health funding requirements are lower than human health programs.
- Stock Repurchase: The Board approved a plan to repurchase up to 100,000 shares. As of June 30, 2003, 5,900 shares were repurchased for approximately $12,267.
- Risks:
- Regulatory: Success depends on FDA approval for new products like Mast Out.
- Market: Sales are negatively affected by low milk prices paid to producers, though some improvement is noted.
- Compliance: The new National Do Not Call Registry (effective Oct 1, 2003) may impact telemarketing efforts for new customer acquisition.
Investor Verification Checklist
- One-Time Gain Impact: Verify the sustainability of earnings by excluding the $1.1 million gain from the AgriCell joint venture sale to assess core operational profitability.
- R&D Burn Rate: Monitor the $193,000 in outside laboratory expenses for Mast Out development and the timeline for FDA pivotal trials to ensure capital sufficiency.
- Revenue Concentration: Note that 93% of product sales for the six-month period came from the U.S. dairy and beef industry, and 21% of sales came from a single customer group.
- Deferred Revenue: Review the $400,000 in deferred revenue from the Maine Technology Institute grant, which carries a contingent payback obligation upon commercialization.